Consistently, Apo2L/TRAIL resistant explanted breast tumour cells were re-sensitised when Apo2L/TRAIL was used in combination with chemotherapeutic drugs including taxol, etoposide, doxorubicin, cisplatin or SAHA [37]: many of these agents are known to enhance PTHrP expression [23]. The gene discussed is PTHLH; the disease is breast neoplasm.